FREDERICK, MD. Nov. 10, 2022—MesaGreen Pharmaceutical Company announced today that the company has filed an Investigational New Animal Drug (INAD) application with the Food and Drug Administration (FDA). The INAD covers the development of the company’s K9MGP product which, when approved, will effectively control an active seizure in dogs that can be used by pet … Read more